Magnin Co-Invents FDA Approved, Onglyza™
Dr. David Magnin, Associate Professor in the Division of Natural Sciences and Mathematics, is a co-inventor of ONGLYZA™, a once-daily tablet which helps to control blood sugar. According to a press release from Bristol-Myers Squibb, “The U.S. Food and Drug Administration (FDA) approved ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor. ONGLYZA is indicated as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults for the treatment of type 2 diabetes mellitus.”
ONGLYZA is a trademark of the Bristol-Myers Squibb Company.